Exelixis (EXEL) EBIT Growth (3y) (2013 - 2026)
Exelixis (EXEL) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBIT Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
719,706.53 Bn |
719,706.50 Bn |
- |
- |
| 2 |
Belite Bio |
55,800.00 Bn |
55,800.00 Bn |
- |
-1,580.97% |
| 3 |
Quantum Biopharma |
18,182.30 Bn |
18,182.29 Bn |
- |
32.96% |
| 4 |
Legend Biotech |
3,154.00 Bn |
3,153.71 Bn |
242.10 Mn |
-29.67% |
| 5 |
Akari Therapeutics |
1,844.30 Bn |
1,844.29 Bn |
- |
-50.81% |
| 6 |
Evaxion A |
1,567.96 Bn |
1,567.94 Bn |
- |
16.35% |
| 7 |
Psyence Biomedical |
251.43 Bn |
251.42 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
112.56 Bn |
105.31 Bn |
2.59 Bn |
13.47% |
| 9 |
Abivax |
94.37 Bn |
94.37 Bn |
- |
- |
| 10 |
Exelixis |
13.37 Bn |
12.59 Bn |
590.86 Mn |
105.81% |
| Date | Value |
|---|
| Apr 3, 2026 |
105.81% |
| Jan 2, 2026 |
90.31% |
| Oct 3, 2025 |
42.00% |
| Jul 4, 2025 |
36.65% |
| Apr 4, 2025 |
30.93% |
| Jan 3, 2025 |
11.41% |
| Sep 27, 2024 |
38.14% |
| Jun 28, 2024 |
30.90% |
| Mar 29, 2024 |
103.24% |
| Dec 29, 2023 |
49.87% |
| Sep 29, 2023 |
25.53% |
| Jun 30, 2023 |
1.01% |
| Mar 31, 2023 |
-18.27% |
| Dec 30, 2022 |
-37.89% |
| Sep 30, 2022 |
-10.60% |
| Jul 1, 2022 |
-3.10% |
| Apr 1, 2022 |
-0.52% |
| Dec 31, 2021 |
1.88% |
| Oct 1, 2021 |
-25.57% |
| Jul 2, 2021 |
12.77% |
